Form 4: Cadrenal CFO Sells Shares Under 10b5-1 Plan

Cadrenal Therapeutics CFO Matthew K. Szot sold a total of 12,400 shares of common stock in two separate transactions in late September 2025 under a pre-arranged trading plan.

Summary

• Matthew K. Szot, Chief Financial Officer of Cadrenal Therapeutics, Inc. (CVKD), reported two sales of common stock.
• On September 24, 2025, Szot sold 1,500 shares of common stock at a weighted average price of $13.9953 per share.
• On September 25, 2025, Szot sold an additional 10,900 shares of common stock at a weighted average price of $14.0534 per share.
• These transactions were conducted pursuant to a Rule 10b5-1(c) trading plan.
• Following the transaction on September 24, 2025, Szot beneficially owned 29,833 shares directly.
• Following the transaction on September 25, 2025, Szot beneficially owned 18,933 shares directly.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While an insider sale reduces executive ownership, the transaction was executed under a Rule 10b5-1 plan, indicating it was pre-scheduled for personal financial management rather than being a discretionary sale based on new information.

Negatives

• The transactions resulted in a reduction of Matthew K. Szot's direct beneficial ownership in Cadrenal Therapeutics, Inc. by a total of 12,400 shares.

Industry Context

This filing reports a routine insider transaction for a Chief Financial Officer, which is a common occurrence across publicly traded companies. The use of a Rule 10b5-1 plan indicates a pre-scheduled sale, often used by executives for personal financial planning, rather than a reaction to immediate company news.

Stakeholder Impact

• Shareholders may note the reduction in direct beneficial ownership by a key executive, although the pre-planned nature of the sale mitigates immediate concerns.

Key Dates

Recommendation

The reported insider sale by the CFO, Matthew K. Szot, was conducted under a Rule 10b5-1 trading plan. Such pre-arranged plans are typically for personal financial diversification and do not necessarily reflect a change in the executive's outlook on the company's future performance. Without additional company-specific news or broader market context, this single Form 4 filing does not provide sufficient grounds to alter a fundamental investment recommendation, thus a 'hold' stance is maintained.

Keywords

Cadrenal Therapeutics, CVKD, Matthew K. Szot, CFO, Insider Trading, Form 4, Stock Sale, 10b5-1 Plan